Which Constituents Actually Matter in a Complex Botanical Extract?

A complex botanical extract can contain dozens, sometimes hundreds, of potential constituents. That creates an obvious regulatory challenge: what should actually be identified, and quantified?

With Clitoria ternatea extract, the answer was not simply “everything we can detect”.

The useful question was: what drives the biological activity?

Fractionation work showed that the insecticidal activity remained with the peptide-containing fraction, supporting cyclotides as the biologically relevant components of interest. At the same time, the other reported constituents could be considered in terms of plausibility, background occurrence and realistic exposure.

That changes the characterisation problem.

The objective is not to produce the longest possible list of detected compounds. It is to understand which components are biologically meaningful, which are relevant to specification, and which may create a credible concern.

For complex biological substances, characterisation should follow biology, not just analytical detectability.

Why Mode-of-Action Matters in Botanical Biopesticide Risk Assessment

Cyclotides are small cyclic peptides found in Clitoria ternatea. Their biological activity appears to involve interaction with cell membranes rather than a highly specific molecular receptor. That distinction matters.

A receptor-mediated mechanism can potentially act at very low concentrations if the right molecular target is present. A membrane-mediated mechanism is different: biological effect depends on sufficient exposure, membrane susceptibility and concentration.

This helps explain an important observation with cyclotides. Insects appear to be more susceptible because the relevant membrane environment is more favourable to cyclotide interaction, while mammalian membranes appear less susceptible.

That does not mean mammalian effects are impossible. It means the risk question becomes more focused:

• Is the organism exposed?
• Is enough material systemically available?
• Are the relevant cells susceptible?
• Are adverse effects actually observed?

Mode-of-action should not be treated as an efficacy curiosity. It can fundamentally change how we frame hazard and exposure.

What Evidence Is Actually Needed for a Robust Botanical Biopesticide Risk Assessment?

Conventional regulatory assessment often starts with a data requirement: which study has not yet been submitted?

For complex biological substances, that may not always be the best scientific starting point.

With Clitoria ternatea extract, we have multiple lines of evidence relevant to mammalian safety: no adverse effects noted, low oral bioavailability of cyclotides, a membrane-mediated mode-of-action with evidence of insect selectivity, and a substantial history of human and livestock exposure.

So when considering additional mammalian assessments, including reproductive and developmental toxicity, the key question should be:

What credible pathway to harm remains unresolved?

For target arthropods, that pathway is clear: exposure, susceptible membranes and observed biological effects.

For mammals, the pathway is much weaker when exposure, systemic availability, susceptibility and existing toxicology are considered together.

That does not mean uncertainty disappears. It means testing should be directed at the uncertainty that matters.

The goal is not less evidence. It is the right evidence.

If you have any queries relating to the botanical biopesticide characterisation or risk assessment, our team of biopesticide regulatory experts are ready to help. Call or email and speak directly with one of our biopesticide consultants.